依普利酮治疗高血压患者的效果好吗？

(Inspra) is a new type of selective aldosterone receptor antagonist that was approved for marketing in the United States in 2002 for the treatment of patients with hypertension. Eplerenone can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that eplerenone can also be used for congestive heart failure after acute myocardial infarction.

Is eplerenone effective in treating patients with hypertension?

Eplerenone treats patients with stage 1 and stage 2 hypertension with similar efficacy rates and reductions in systolic and diastolic blood pressure as enalapril. Eplerenone (Inspra) also has a good antihypertensive effect in patients with essential hypertension with low renin levels who do not respond well to angiotensin-converting enzyme inhibitors and angiotensin receptor inhibitors. It also has a good antihypertensive effect on simple systolic hypertension, and has a good antihypertensive effect on diet-induced obesity-related hypertension. In addition, eplerenone can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for hypertensive patients with diabetes.

It can be seen that eplerenone (Inspra) is very effective in treating patients with hypertension, and it has a positive effect whether it is a single drug or combined with antihypertensive drugs. For oral administration, the initial dose is 50 mg, once a day; the maintenance dose is 50 mg, 1-2 times a day. The maximum dose is 100 mg/day and patients should not overdose.

As the first selective aldosterone receptor antagonist, (Inspra) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension. The "China Guidelines for the Prevention and Treatment of Hypertension 2010" also proposed eplerenone as one of the main antihypertensive drugs.

Recommended related hot articles: /newsDetail/73023.html